Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Capeserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 9/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.36 |
| ▸ | HTR3B | O95264 | 2/20 | 0.36 |
| ▸ | HTR3A | P46098 | 2/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Capeserod SCHEMBL399091 | 0.99 | HTR4 (0.44) | HTR4CNR1GPR55CHRM2CHRM3 | |
| SCHEMBL8306432 | 0.85 | HTR4 (0.53) | HTR4HTR2CHTR2AHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL8364693 | 0.84 | HTR4 (0.52) | HTR4HTR2CHTR2AHTR2BSIGMAR1 | |
| SCHEMBL8303718 | 0.83 | HTR4 (0.52) | HTR4 | |
| SCHEMBL8305672 | 0.83 | DRD2 (0.44) | CNR1GPR55CHRM2CHRM3HTR2C | |
| SCHEMBL8308397 | 0.83 | HTR4 (0.49) | HTR4CHRM2CHRM3HTR2CDRD2 | |
| Bromide SCHEMBL8369649 | 0.82 | HTR4 (0.51) | HTR4 | |
| Hydrochloric Acid SCHEMBL8369921 | 0.82 | DRD2 (0.45) | CNR1GPR55CHRM2CHRM3HTR2C | |
| SCHEMBL8309195 | 0.81 | HTR4 (0.42) | HTR4CNR1GPR55HTR2CDRD2 | |
| SCHEMBL8309535 | 0.80 | DRD4 (0.44) | HTR4HTR2CDRD2HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414575-A1 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS INC (US) | 2023-12-28 | — | — | US | claimed |
| EP-4281065-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF DEPRESSION AND RELATED CONDITIONS | Alto Neuroscience, Inc. (US) | 2023-11-29 | — | — | EP | claimed |
| EP-4244341-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | Akttyva Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| US-20230117508-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH DEPRESSIVE, ANHEDONIA, MOTIVATION-RELATED OR COGNITION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE, INC. | 2023-04-20 | — | — | US | claimed |
| US-20220273680-A1 | Methods of Treating Psychological and Brain Disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-09-01 | — | — | US | claimed |
| WO-2022159632-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF DEPRESSION AND RELATED CONDITIONS | ALTO NEUROSCIENCE, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20220226302-A1 | ENHANCEMENT OF CAMP SIGNALING AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF DEPRESSION AND RELATED CONDITIONS | ALTO NEUROSCIENCE, INC. | 2022-07-21 | — | — | US | claimed |
| CN-114599355-A | Method for treating psychological and cerebral diseases | 马里兰大学巴尔的摩分校 | 2022-06-07 | — | — | CN | claimed |
| WO-2022104097-A2 | MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS | AKTTYVA THERAPEUTICS, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-1904037-A1 | PROLONGED RELEASE FORMULATION OF ACTIVE PRINCIPLES HAVING A PH-DEPENDENT SOLUBILITY | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | claimed |
| WO-2007003746-A1 | PROLONGED RELEASE FORMULATION OF ACTIVE PRINCIPLES HAVING A PH-DEPENDENT SOLUBILITY | SANOFI-AVENTIS (FR) | 2007-01-11 | — | — | WO | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| EP-4706758-A2 | METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20220031684-A1 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2022-02-03 | — | — | US | disclosed |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
| CN-105979959-B | Compounds and methods for inhibiting phosphate transport | 阿德利克斯公司 | 2021-11-30 | — | — | CN | disclosed |
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885CNR1 4249/4885GPR55 3299/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | HTR4 314/4885CNR1 23/4885GPR55 89/4885 |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM2 | HTR4 60/4885CNR1 32/4885GPR55 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.